Physician profile
Ryan Gini
NPI 1164471769
$7,935.44
in general payments reported to CMS, 2019-2025
47 companies · $1,332 in 2025
The $1,332 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $719 · 2020: $1,132 · 2021: $1,424 · 2022: $949 · 2023: $1,416 · 2024: $963 · 2025: $1,332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,711.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,093.29 | 2021-2025 | |
| Amgen INC. | $801.25 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals Lp | $647.53 | 2019-2025 | Saphnelo, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $632.18 | 2019-2024 | Xarelto, Spravato |
| Amarin Pharma, INC. | $598.15 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $426.09 | 2021-2025 | |
| Glaxosmithkline, LLC. | $376.47 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $333.29 | 2020-2025 | Zepbound, Jardiance, Mounjaro |
| Pfizer INC. | $324.59 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $324.47 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $281.32 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $256.32 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Novo Nordisk INC | $207.30 | 2020-2025 | Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $177.71 | 2023-2025 | |
| Exact Sciences Corporation | $96.63 | 2023-2025 | Cologuard Collection Kit |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Gini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.